Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;26(7):e3717.
doi: 10.1002/jgm.3717.

Hematopoietic stem cell gene therapy for the treatment of SYNGAP1-related non-specific intellectual disability

Joseph S Anderson  1 , Alyse L Lodigiani  1 , Camilla M Barbaduomo  1 , Julie R Beegle  1
Affiliations

Hematopoietic stem cell gene therapy for the treatment of SYNGAP1-related non-specific intellectual disability

Joseph S Anderson et al. J Gene Med. 2024 Jul.

Abstract

Background: Synaptic Ras GTPase activating protein 1 (SYNGAP1)-related non-specific intellectual disability is a neurodevelopmental disorder caused by an insufficient level of SynGAP1 resulting in a dysfunction of neuronal synapses and presenting with a wide array of clinical phenotypes. Hematopoietic stem cell gene therapy has the potential to deliver therapeutic levels of functional SynGAP1 to affected neurons upon transduction of hematopoietic stem and progenitor cells with a lentiviral vector.

Methods: As a novel approach toward the treatment of SYNGAP1, we have generated a lentiviral vector expressing a modified form of SynGAP1 for transduction of human CD34+ hematopoietic stem and progenitor cells. The gene-modified cells were then transplanted into adult immunodeficient SYNGAP1+/- heterozygous mice and evaluated for improvement of SYNGAP1-related clinical phenotypes. Expression of SynGAP1 was also evaluated in the brain tissue of transplanted mice.

Results: In our proof-of-concept study, we have demonstrated significant improvement of SYNGAP1-related phenotypes including an improvement in motor abilities observed in mice transplanted with the vector transduced cells because they displayed decreased hyperactivity in an open field assay and an increased latency to fall in a rotarod assay. An increased level of SynGAP1 was also detected in the brains of these mice.

Conclusions: These early-stage results highlight the potential of this stem cell gene therapy approach as a treatment strategy for SYNGAP1.

Keywords: SYNGAP1; gene therapy; hematopoietic stem cells; lentiviral vector; neurodevelopmental disorders.

PubMed Disclaimer

References

REFERENCES

    1. Kilinc M, Creson T, Rojas C, et al. Species‐conserved SYNGAP1 phenotypes associated with neurodevelopmental disorders. Mol Cell Neurosci. 2018;91:140‐150. doi:10.1016/j.mcn.2018.03.008
    1. Holder JL, Hamdan FF, Michaud JL. SYNGAP1‐related intellectual disability. In: Adam MP et al., eds. GeneReviews®. University of Washington; 2019.
    1. Gamache TR, Araki Y, Huganir RL. Twenty years of SynGAP research: from synapses to cognition. J Neurosci. 2020;40(8):1596‐1605. doi:10.1523/JNEUROSCI.0420‐19.2020
    1. Jeyabalan N, Clement JP. SYNGAP1: mind the gap. Front Cell Neurosci. 2016;10:32. doi:10.3389/fncel.2016.00032
    1. Kim JH, Lee H‐K, Takamiya K, Huganir RL. The role of synaptic GTPase‐activating protein in neuronal development and synaptic plasticity. J Neurosci. 2003;23(4):1119‐1124. doi:10.1523/JNEUROSCI.23‐04‐01119.2003

Substances

Grants and funding